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Abstract
Background: Several lines of evidence indicate that decompensated cirrhosis is charac‐
terized by the presence of systemic inflammation. Hepatorenal syndrome (HRS‐AKI) is a 
unique type of renal failure that occurs at late stages of cirrhosis. However, confirmation 
of the presence and significance of such inflammatory response in HRS‐AKI is lacking.
Aim and Methods: To characterize the systemic inflammatory response, as estimated 
by measuring a large number of cytokines, in 161 patients hospitalized for an acute 
decompensation of cirrhosis: 44 patients without acute kidney injury (AKI), 63 pa‐
tients with hypovolaemia‐induced AKI and 58 patients with HRS‐AKI.
Results: HRS‐AKI was characterized by an altered cytokine profile compared to the 
other two groups, particularly IL‐6, IL‐8, TNF‐α, VCAM‐1, fractalkine and MIP‐1α. 
The inflammatory response was not related to presence of bacterial infection, con‐
comitant acute‐on‐chronic liver failure or severity of renal dysfunction. Patients who 
responded to terlipressin and albumin had only a decrease in TNF‐α and RANTES 
after treatment without changes in other cytokines. Interestingly, patients with per‐
sistent HRS‐AKI had higher levels of IP‐10 and VCAM‐1 compared to those with 
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1  | INTRODUCTION
Hepatorenal syndrome (HRS) is a unique type of acute kidney injury 
(AKI), currently known as (HRS‐AKI), which develops in patients with 
decompensated cirrhosis and is considered a very severe complica‐
tion of the disease at the end of the spectrum of complications of 
cirrhosis.1,2
A large body of evidence demonstrating that circulatory dys‐
function plays a key role in the pathophysiology of HRS‐AKI.2‐4 It 
has been shown that HRS‐AKI occurs as a consequence of an in‐
tense renal vasoconstriction with marked reduction in renal blood 
flow and glomerular filtration rate (GFR), which is pathogenically 
related to a striking splanchnic arterial vasodilatation with activa‐
tion of major vasoconstrictor systems, as a consequence of portal 
hypertension.4,5 Administration of vasoconstrictors, particularly 
terlipressin, in association with albumin, improves circulatory func‐
tion and is able to return renal function to baseline values in many 
patients, which confirms the major role of circulatory dysfunction 
with arterial vasodilation in the pathogenesis of kidney impairment 
in HRS‐AKI.6,7
In recent years, it has become increasingly evident that cirrhosis is 
a condition with marked systemic inflammatory state, which appears 
to increase with disease progression, from compensated to decom‐
pensated cirrhosis, and is related to patient outcome.8,9 Some clinical 
studies have assessed inflammation by measuring leucocyte count 
or C‐reactive protein (CRP) levels,10 while others have assessed the 
prevalence of systemic inflammatory response syndrome (SIRS)11; 
however, these methods are not very accurate in the evaluation of 
inflammation. Besides, studies in experimental animals have also 
demonstrated the existence of systemic inflammation that is more 
conspicuous in animals with ascites compared to those without.12 
Finally, few studies have evaluated a large number of inflammatory 
cytokines and confirmed the presence of systemic inflammation, as 
estimated by increased plasma levels of relevant cytokines involved 
in inflammation, which increase with disease progression.8,13,14 The 
hypothesis, therefore, has been raised that cirrhosis is a disease 
characterized by marked and progressive systemic inflammation that 
may play a role in the development of complications of the disease.15 
However, so far there is lack of information regarding the presence, 
extent and significance of inflammation in patients with HRS‐AKI. 
Given that HRS‐AKI is considered the hallmark of the disease, this 
information may be relevant not only with respect to pathogenesis 
but also for identification of potential targets of therapy to prevent 
disease progression.
On this background, the aim of our study was to assess the ex‐
istence of systemic inflammation, as estimated by plasma levels of a 
large number of inflammatory cytokines, in patients with HRS‐AKI 
and investigate the relationship between inflammation and kidney 
and patient outcomes. Because systemic inflammation is common in 
ACLF and patients with HRS‐AKI frequently meet diagnostic criteria 
of ACLF, the role of this latter condition as potential cause of inflam‐
mation in HRS‐AKI was also assessed.
2  | PATIENTS AND METHODS
2.1 | Patient population and study design
One‐hundred and sixty‐five episodes of AKI occurring in 161 pa‐
tients with decompensated cirrhosis admitted to the Liver Unit of 
Hospital Clinic were investigated in the current study. These patients 
were selected from a prospective database with Biobank collection 
resolution of HRS‐AKI. VCAM‐1 was also an independent predictor of 3‐month mor‐
tality. A systems biology analysis approach showed that the inflammatory status of 
HRS‐AKI was similar to that of chronic nonhepatic inflammatory conditions, such as 
lupus erythematosus or inflammatory bowel disease.
Conclusion: Hepatorenal syndrome is characterized by a marked systemic inflamma‐
tory state, reminiscent of that of nonhepatic inflammatory diseases, that correlates 
with patient outcomes.
K E Y WO RD S
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LAY SUMMARY
• Hepatorenal syndrome, a type of renal dysfunction that 
occurs at the end stage of cirrhosis, is characterized by a 
marked systemic inflammatory state.
• Lack of resolution of renal impairment and short‐term 
mortality are associated with increased levels of some 
inflammatory markers; IL‐6, IL‐8, TNF‐α, ICAM‐1 and 
particularly, VCAM‐1.
• A systems biology analysis approach showed that the 
inflammatory status of hepatorenal syndrome was simi‐
lar to that found in chronic nonhepatic inflammatory 
diseases, such as lupus erythematosus or inflammatory 
bowel disease.
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that includes consecutive patients with cirrhosis admitted to hospi‐
tal for treatment of an acute decompensation of the disease. Three 
groups of subjects were identified randomly from the database: (1) 
patients with decompensated cirrhosis without AKI (N = 44), (2) pa‐
tients with hypovolaemia‐induced AKI (N = 63) and (3) patients with 
HRS‐AKI (N = 58). Forty‐one of the 58 patients (71%) with HRS‐AKI 
met the classical criteria of type‐1 HRS.16 Exclusion criteria were 
previous kidney/liver transplantation, chronic haemodialysis before 
admission, hepatocellular carcinoma outside the Milan criteria or any 
other advanced malignancy, and lack of inform consent.
Demographical, clinical and analytical data were collected pro‐
spectively at admission and at regular intervals during hospitalization, 
and patients were followed up for at least 3 months after discharge. 
Blood and urine samples were collected at the time of inclusion in this 
study. Moreover, in 27 patients with type 1‐HRS, samples were also 
collected after treatment with terlipressin and albumin (median time 
between the two sample collections was of 7 days). Blood was centri‐
fuged at 2000 g, at 4°C, for 10 min, and plasma was stored at −80°C 
until analysis. All samples were stored at the Biobank as required 
by Spanish legislation. This study was approved by the Institutional 
Review Board of our centre, the research Ethic Committee of the 
Hospital Clínic of Barcelona (HCB/2017/0285), and all patients signed 
a written informed consent for participation in this study.
2.2 | Multiplex cytokine assay
The following 18 cytokines and vascular adhesion molecules 
were determined in plasma with the Luminex® Immunoassay Kit 
(Panomics®, Affymetrix Inc, Santa Clara, CA, USA): eotaxin, G‐
CSF, fractalkine, IFN‐γ, IL‐10, IL‐1RA, IL‐1β, IL‐6, IL‐8, IP‐10, MCP‐1, 
MIP‐1α, MIP‐1β, TNF‐α, VEGF, ICAM‐1, VCAM‐1 and RANTES (see 
Supplementary materials). Urine MCP‐1 was also analysed (R&D® 
Systems, Minneapolis, MN, USA). Cytokines IL‐10, IL‐1RA and IL‐1β 
were excluded from statistical analyses because their levels were 
out of the detection limit in more than 30% of the samples.
2.3 | Definitions
AKI and ACLF were defined according to ICA1 and CANONIC17 defi‐
nitions respectively (see Supplementary materials).
2.4 | Statistical analysis
Comparisons of normally distributed continuous variables were 
made with Student's t test or ANOVA. Comparisons of non‐normally 
distributed continuous variables were made with Mann‐Whitney 
U or Kruskal‐Wallis tests. Results for continuous variables are ex‐
pressed as median and interquartile range (IQR). Categorical vari‐
ables were expressed as number and percentage and compared with 
the chi‐square test or Fisher exact test. Survival curves were calcu‐
lated with Kaplan and Meier method and compared with log‐rank 
test. Due to the lack of prior knowledge on the relevance of cut‐off 
levels for quantitative variables, we decided to use the unsupervised 
criterion of the median value. Multivariate Cox regression was per‐
formed to identify the independent factors associated with mortal‐
ity. There was no specific calculation of the sample size. However, 
based on previous experience studies in patients with cirrhosis,14,18 
it was considered that more than 100 patients had to be included in 
this study to achieve a significant number of outcomes in terms of 
lack of AKI resolution and 3‐month mortality. All statistical analyses 
were performed using SPSS statistical package, version 23.0. The 
significance level for all tests was set at 0.05 two‐tailed.
2.5 | Systems biology analysis
We used a systems biology approach based on artificial neural 
networks supervised algorithm (ANN algorithm) that measures 
the strength of relationships between groups of human proteins.19 
Measures are based on the topology of the network, and the training 
set is derived mostly from drug effects. The conditions used were 
those defined in BED (Biological Effectors Database, Anaxomics 
Biotech, Barcelona, Spain) a hand‐curated collection of scientific 
knowledge relating biological processes to their molecular effectors. 
The ANN algorithm provides a predictive score (from 0% to 100%) 
that quantifies the amount and strength of relationships between 
the evaluated proteins. Each score is associated with a P value that 
describes the probability of the results being a true positive re‐
sult19,20 (see Supplementary materials).
3  | RESULTS
3.1 | Baseline characteristics of patients
The baseline characteristics of patients with decompensated cirrho‐
sis included in this study categorized into 3 groups (no AKI, hypovol‐
aemia‐induced AKI and HRS‐AKI) are shown in Table 1. Of interest, 
bacterial infections were more common in patients with HRS‐AKI 
compared to the other two groups, a finding consistent with the 
known role of bacterial infections as triggering factors of HRS‐AKI. 
As expected, the frequency and severity of ACLF were higher in pa‐




The prevalence of SIRS, leucocyte count and serum CRP levels were 
higher in patients with HRS‐AKI compared to the other two groups 
(Table 2). With respect to cytokine levels, patients with HRS‐AKI had 
a cytokine profile different from that in the other two groups, with 
statistically significant differences in the levels of several cytokines, 
including higher urinary levels of MCP‐1 and plasma IL‐6, TNF‐α, 
VCAM‐1, and IL‐8, and lower levels of MIP1‐α and fractalkine.
To further explore the cytokine profile of HRS‐AKI, we assessed 
whether the increased cytokine levels found in these patients could 
be related to concomitant bacterial infections that were more 
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common in this group of subjects. With this objective, we compared 
cytokine levels in patients with HRS‐AKI categorized according to 
presence or absence of infection (42 and 16 patients, respectively) 
(Supplementary Table 1). Out of the 5 cytokines that were differen‐
tially increased in patients with HRS‐AKI, only plasma IL‐6 was sig‐
nificantly higher in patients with HRS‐AKI associated with infections 
compared to those without infections (59 (21‐180) vs 23 (12‐55) pg/
mL, respectively, P = 0.02). However, it is possible that a further ag‐
gravation of the increased systemic inflammation during HRS‐AKI 
associated with bacterial infections could not be detected due to the 
low number of patients with HRS‐AKI without infections.
Next, we analysed whether severity of kidney impairment in HRS‐
AKI correlated with the intensity of systemic inflammatory response. 
As shown in Supplementary Table 2, categorization of patients with 
HRS‐AKI in those who met the diagnostic criteria of type‐1 HRS, the 
most severe form of HRS‐AKI, and those who did not meet these cri‐
teria, showed no significant differences with respect to frequency of 
SIRS, leucocyte count and CRP, as well as cytokine levels. In the HRS‐
AKI group, serum creatinine levels did not correlated with inflammatory 
biomarkers, except for urinary levels of MCP‐1 (r = 0.420, P = 0.002).
We also investigated whether reversal of kidney impairment in 
patients with HRS‐AKI was associated with changes in cytokine pro‐
file. To this purpose, we compared cytokine levels before and after 
kidney function improvement in 24 patients with type‐1 HRS treated 
with vasoconstrictors and albumin. As expected, serum creatinine 
decreased significantly after treatment (from 2.9 to 1.3 mg/dL; 
P < 0.001). Out of all cytokines evaluated, only plasma TNF‐α and 
RANTES decreased significantly and MIP‐1α increased with reversal 
of kidney dysfunction (Table 3).
Since many patients with HRS‐AKI meet the criteria of ACLF, we 
investigated whether the increased levels of inflammatory cytokines 
found in HRS‐AKI were potentially related to the presence of con‐
comitant ACLF. To this aim, we categorized patients with HRS‐AKI 
according to the presence or absence of ACLF. As shown in Table 4, 
patients with HRS‐AKI with associated ACLF had levels of cytokines 
that were similar to those of patients with HRS‐AKI without ACLF. 
Moreover, the levels of cytokines did not correlate with ACLF sever‐
ity, except for higher levels of IL‐8 and ICAM‐1 in patients with ACLF 
grades 2‐3 vs those of patients with grade 1 (Table 5). To further ex‐
plore the relationship between AKI and ACLF, we compared inflam‐
matory cytokine levels in patients with ACLF categorized according 
to AKI type, either HRS‐AKI or hypovolaemia‐induced AKI. Patients 
with ACLF associated with HRS‐AKI had higher levels of IL‐6, TNF‐α 
and urinary MCP‐1 and lower levels of fractalkine and MIP1‐α com‐
pared to the hypovolaemia‐induce AKI counterparts (data not shown).
3.3 | Relationship of systemic inflammatory 
response and cytokine levels with kidney 
outcome and patient survival
Out of the 121 patients with AKI, resolution of kidney function im‐
pairment was observed in 86 (71%), whereas the remaining 35 (29%) 
TA B L E  1   Baseline demographical, clinical and laboratory characteristics of patients included in this study
No AKI (N = 44)
Hypovolaemia‐induced AKI 
(N = 63) HRS‐AKI (N = 58) P value
Age, years 62 (56‐70) 62 (54‐67) 59 (53‐66) 0.556
Diabetes mellitus 14 (32) 21 (33) 16 (28) 0.783
Male gender 30 (68) 43 (68) 45 (78) 0.445
Aetiology of cirrhosis: Alcohol/
hepatitis C
24 (55)/10 (23) 26 (41)/15 (24) 28 (48)/12 (21) 0.558
Ascites 23 (52) 44 (67) 58 (100) <0.001
Hepatic encephalopathy 3 (7) 12 (19) 28 (48) <0.001
Bacterial infection 22 (50) 20 (32) 42 (72) <0.001
Serum creatinine (mg/dL) 0.8 (0.6‐1.0) 1.6 (1.3‐1.9) 2.6 (1.9‐3.1) <0.001
Serum bilirubin (mg/dL) 2.5 (1.4‐3.9) 2.6 (1.6‐5) 4.2 (2.4‐11.2) 0.004
INR 1.5 (1.3‐1.6) 1.5 (1.3‐1.9) 1.9 (1.5‐2.2) <0.001
Serum sodium (mEq/L) 137 (134‐140) 135 (132‐139) 131 (127‐135) <0.001
Platelet count (×109/L) 85 (56‐140) 77 (49‐110) 76 (50‐103) 0.441
Mean arterial pressure (mm Hg) 82 (76‐92) 77 (69‐87) 74 (68‐84) 0.010
MELD score 14 (12‐18) 19 (15‐24) 28 (23‐34) <0.001
Child‐Pugh score 8 (6‐9) 8 (7‐10) 11 (9‐12) <0.001
ACLF
Frequency 0 27 (43) 49 (84) <0.001
Grade 1 vs 2/3 – 21/6 26/23 <0.001
INR, International normalized ratio; MELD, model for end‐stage liver disease.
Values are number and percentages (in brackets) or median and interquartile range (in brackets).
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patients had persistent AKI. Patients with persistent AKI had signifi‐
cantly higher baseline leucocyte count and CRP levels and plasma 
IL‐6 and VCAM‐1 compared to those of patients with AKI resolu‐
tion. In the group of patients with HRS‐AKI, those with persistent 
AKI (27 patients, 47%) showed significantly higher leucocyte count 
and plasma levels of IP‐10 and VCAM‐1 compared to those who had 
resolution of HRS‐AKI (31 patients, 53%), yet differences of these 
latter two cytokines were barely significant (Table 6).
At the end of the 3‐month follow‐up period, 110 patients 
(69%) were alive, 34 (21%) had died, and 15 (9%) had been trans‐
planted and 2 were lost to follow‐up. Interestingly, a number of 
inflammatory parameters and cytokines correlated with 3‐month 
mortality: leucocyte count, CRP levels and plasma IL‐6, IL‐8, 
TNF‐α, ICAM‐1 and VCAM‐1. In multivariate analysis, including 
those inflammatory variables that were associated with mortality 
in the univariate analysis, only plasma VCAM‐1 was an indepen‐
dent predictive factor of 3‐month mortality. Plasma VCAM‐1 was 
also the only inflammatory marker independently predictive of 
3‐month mortality in the group of patients with HRS‐AKI (3156 
(2029‐4349) vs 1944 (1535‐2829) ng/mL, for patients who died 
and survived at 3 months, respectively; P < 0.01), even when ad‐
justed for the presence and severity of ACLF. Survival probability 





We used a systems biology approach based on artificial neural 
networks that measures the strength of relationships between 
groups of human proteins in order to compare the extent of sys‐
temic inflammation in HRS‐AKI with that of other conditions char‐
acterized by well‐defined and marked systemic inflammatory status. 
Interestingly, the cytokine pattern of HRS‐AKI was related to that of 
a number of inflammatory conditions, including cystic fibrosis, rheu‐
matoid arthritis, systemic lupus erythematosus, Crohn's disease and 
ulcerative colitis (predictive value > 70) (Figure 2).
4  | DISCUSSION
The results of the current study show that patients with HRS‐AKI 
have marked systemic inflammation with altered cytokine pro‐
file compared to that of patients with decompensated cirrhosis 
without AKI and, most interestingly, to patients with AKI due to 
hypovolaemia. The systemic inflammatory response in HRS‐AKI 
does not seem to be related to presence of bacterial infections, 
concomitant ACLF or intensity of kidney dysfunction and is not 
TA B L E  2   Comparison of systemic inflammatory markers and plasma and urine cytokine levels between the 3 groups of patients
No AKI (N = 44)
Hypovolaemia‐induced AKI 
(N = 63) HRS‐AKI (N = 58) P value
C‐reactive protein (mg/dL) 1.6 (0.5‐3.9) 1.0 (0.4‐2.2) 3 (1.7‐6.1) <0.001
Leucocyte count (×109/L) 5 (4‐7) 5 (4‐8) 7 (4‐11) 0.046
SIRS 7 (16) 10 (16) 17 (33) 0.053
Plasma cytokines
IL‐6 (pg/mL) 14 (3‐46) 14 (3‐46) 45 (19‐104) <0.001
TNF‐α (pg/mL) 22 (17‐39) 30 (19‐50) 47 (35‐61) <0.001
Fractalkine (pg/m) 111 (19‐559) 363 (88‐21924) 111 (29‐377) 0.004
MIP1‐α (pg/mL) 2048 (12‐3970) 41 (13‐3970) 14 (6‐52) 0.005
VCAM‐1 (ng/mL) 1816(1249‐2662) 2184(1659‐2866) 2410(1850‐3731) 0.006
IL‐8 (pg/mL) 25 (12‐75) 45 (18‐90) 56 (37‐92) 0.009
VEGF (pg/mL) 453 (75‐19,715) 179 (104‐1681) 166 (71‐539) 0.088
G‐CSF (pg/mL) 30 (3‐82) 14 (3‐41) 30 (6‐58) 0.132
MCP‐1 (pg/mL) 269 (175‐376) 284 (214‐444) 340 (212‐472) 0.370
RANTES (pg/mL) 7458 (1937‐23,962) 4515 (2040‐17,985) 4399 (1293‐20,774) 0.449
INF‐γ (pg/mL) 29 (5‐88) 37 (14‐129) 35 (13‐122) 0.454
IP‐10 (pg/mL) 961 (592‐1671) 1000 (594‐2067) 1206 (690‐2014) 0.556
ICAM‐1 (ng/mL) 269 (215‐500) 279 (215‐377) 306 (234‐443) 0.596
Eotaxin (pg/mL) 115 (78‐157) 101 (68‐161) 109 (84‐143) 0.772
MIP1‐β (pg/mL) 40 (15‐91) 30 (21‐72) 36 (23‐80) 0.779
Urinary cytokines
uMCP‐1 (pg/mL) 408 (207‐1257) 443 (193‐1340) 1292 (689‐3356) <0.001
SIRS; Systemic inflammatory response.
Values are number and percentages (in brackets) or median and interquartile range (in brackets).
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normalized by improvement of kidney function with pharmaco‐
logical therapy. Interestingly, the intensity of the inflammatory 
response is correlated with kidney and patient outcomes in such a 
way that increased levels of some inflammatory markers, particu‐
larly VCAM‐1, are associated with lack of resolution of AKI and 
mortality.
In the current study, a large number of consecutive patients 
with cirrhosis and HRS‐AKI were investigated for the presence of 
systemic inflammatory response as assessed by a large number 
of inflammatory and anti‐inflammatory cytokines using multiplex 
technology. A control group of patients with decompensated cir‐
rhosis without AKI was included for comparison. A group of pa‐
tients with decompensated cirrhosis with AKI due to hypovolaemia 
was also studied. This type of AKI was selected as comparator for 
HRS‐AKI because in both conditions AKI is of prerenal origin, yet 
the underlying pathogenic cause is very different. While a con‐
tracted blood volume is the cause of renal hypoperfusion in the 
former, the impairment of kidney function in the latter is related 
to opposite circulatory features, namely markedly dilated vascular 
bed, particularly in the splanchnic circulation.2‐4 The results of the 
current study clearly show that as decompensated cirrhosis pro‐
gresses towards HRS‐AKI, there is progressive increase in inflam‐
matory status with significantly increased levels of some powerful 
inflammatory cytokines. Previous studies have shown that plasma 
levels of inflammatory cytokines are significantly increased in 
decompensated compared to compensated cirrhosis, suggesting 
TA B L E  3   Systemic inflammatory markers and plasma and urine 
cytokine levels in patients with type 1 HRS‐AKI before and after 
effective treatment with terlipressin and albumin
Baseline (N = 24)
Terlipressin and 








4.9 (2.5‐6.7) 1.3 (1.2‐1.5) 0.008
Leucocyte 
count (×109/L)
7 (2.9‐11) 5 (3‐9) 0.246
Plasma 
cytokines
Eotaxin (pg/mL) 104 (78‐130) 115 (85‐144) 0.909
G‐CSF (pg/mL) 31 (9‐68) 18 (3‐41) 0.259
Fractalkine (pg/
mL)
140 (13‐679) 79 (13‐835) 0.475
INF‐γ (pg/mL) 73 (25‐165) 39 (18‐111) 0.230
IL‐6 (pg/mL) 73 (16‐95) 32 (7‐58) 0.128
IL‐8 (pg/mL) 62 (38‐78) 54 (38‐94) 0.648
IP‐10 (pg/mL) 1457 (563‐2067) 884 (519‐1258) 0.116
MCP‐1 (pg/mL) 337 (189‐401) 283 (222‐384) 0.753
MIP1‐α (pg/mL) 10 (6‐47) 46 (9‐3970) 0.030
MIP1‐β (pg/mL) 50 (18‐93) 31 (14‐52) 0.073
TNF‐α (pg/mL) 48 (33‐67) 30 (22‐52) 0.007
VEGF (pg/mL) 181 (87‐485) 163 (58‐961) 0.223






















Values are number and percentages (in brackets) or median and inter‐
quartile range (in brackets).
TA B L E  4   Comparison of systemic inflammatory markers and 
plasma and urine cytokine levels in patients with HRS‐AKI 










3 (2‐4) 3 (2‐6) 0.552
Leucocyte 
count (×109/L)
7 (5‐9) 7 (4‐11) 0.991
SIRS 3 (33) 14 (33) 1.000
Plasma 
cytokines
Eotaxin (pg/mL) 114 (85‐269) 108 (82‐134) 0.439
G‐CSF (pg/mL) 30 (4‐102) 30 (8‐56) 0.880
Fractalkine 
(pg/L)
133 (44‐662) 106 (24‐307) 0.805
INF‐γ (pg/mL) 97 (22‐302) 31 (12‐94) 0.179
IL‐6 (pg/mL) 21 (19‐76) 47 (18‐137) 0.629
IL‐8 (pg/mL) 46 (35‐83) 60 (37‐99) 0.599
IP‐10 (pg/mL) 1096 (816‐2933) 1232 (671‐1957) 0.660
MCP‐1 (pg/mL) 265 (148‐656) 344 (216‐463) 0.755
MIP1‐α (pg/mL) 41 (12‐2011) 13 (5‐52) 0.218
MIP1‐β (pg/mL) 30 (20‐87) 39 (24‐75) 0.540
TNF‐α (pg/mL) 51 (38‐53) 46 (33‐62) 0.755
VEGF (pg/mL) 146 (79‐10,184) 168 (64‐394) 0.547
ICAM‐1 (ng/mL) 285 (217‐449) 314 (239‐439) 0.739
VCAM‐1 (ng/
mL)














736 (647‐1364) 1382 (810‐3543) 0.213
SIRS; systemic inflammatory response.
Values are number and percentages (in brackets) or median and inter‐
quartile range (in brackets).
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the existence of an inflammatory driving force that occurs with 
the progression of the disease.8,9 Whether this inflammatory 
driving force is cause or consequence of progression of liver dis‐
ease is not known. Our data confirm that this inflammatory status 
across decompensated cirrhosis increases even more as the dis‐
ease progresses towards HRS‐AKI which is considered one of the 
latest stages of cirrhosis, given its high mortality rate. Our data 
therefore are in agreement with the recently proposed theory of 
systemic inflammation driving the complications of cirrhosis.15 
Further support to this theory comes from our systems biology 
analyses showing that systemic inflammation in cirrhosis is similar 
to that found in some key chronic inflammatory conditions, such 
as inflammatory bowel diseases, rheumatoid arthritis or systemic 
lupus erythematosus.
One relevant issue of the current study is whether the increased 
inflammatory state observed in patients with HRS‐AKI was due to 
‘hepatorenal syndrome’ itself or the presence of concomitant ACLF, 
since it has been shown that the latter condition is characterized by 
a marked systemic inflammation.13,14 Two lines of evidence suggest 
TA B L E  5   Comparison of systemic inflammatory markers and 
plasma and urine cytokine levels in patients with HRS‐AKI 
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SIRS; systemic inflammatory response.
Values are number and percentages (in brackets) or median and inter‐
quartile range (in brackets).
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that the increased inflammatory state is not related to ACLF. Firstly, 
patients with HRS‐AKI but without ALCF had plasma cytokine lev‐
els that were not significantly different from those found in patients 
with HRS‐AKI with ACLF. Moreover, cytokine levels were largely 
unrelated to ACLF grade. On the other hand, cytokine profile of pa‐
tients with HRS‐AKI was noticeably different from that of patients 
with ACLF associated with hypovolaemia‐induced AKI, suggesting 
that cytokine profile was mostly related to ‘hepatorenal syndrome’ 
and not to ACLF. Nevertheless, these findings should be taken with 
caution because of the relatively low number of patients included 
which prevented performing a propensity score matching analysis. 
Further studies are needed to try to dissect out whether systemic 
inflammation is due to hepatorenal syndrome ‘per se’ or to ACLF, 
or both.
A final issue that deserves discussion is that patients in whom 
HRS‐AKI persisted showed higher levels of some inflammatory mark‐
ers, the most important of which appears to be VCAM‐1. Moreover, 
VCAM‐1 was also an independent predictive factor of survival in the 
whole series of patients. VCAM‐1 is an inflammatory mediator that 
plays a central role in triggering the process of systemic inflamma‐
tion in response to several stimuli by helping recruit inflammatory 
cells outside of the systemic circulation.21 Few previous studies have 
shown the potential relevance of VCAM‐1 as prognostic indicator 
of patients with cirrhosis.22 Our results extend these observations 
by showing that among a large number of inflammatory markers, 
VCAM‐1 plasma levels are associated with lack of resolution of 
HRS‐AKI and poor survival. These results together with findings of a 
similar inflammatory profile compared to that of some inflammatory 
diseases shed light on the potential role of VCAM‐1 and TNF‐α as 
therapeutic targets in patients with advanced cirrhosis.23
The current study has some limitations that should be acknowl‐
edged. Firstly, some cytokines, such as IL‐10 and IL‐1RA, were out‐
side of the range detection limit established for the multiplex assay 
and could not be evaluated. The multiplex methodology allows the 
measurement of cytokines in little volume and in the same sample 
well. To achieve this multiplexing, the quantification of analytes is 
performed with serial dilutions of a common calibrator.  Therefore, 
the individual adjustment of the detection limit for each analyte is 
not possible with the consequent lost of quantification in the case of 
some cytokines included in the multiplexing. This problem could be 
solved by performing high sensitivity immunoanalytical methods for 
single analytes, but due to limitations in the available sample volume, 
F I G U R E  1   Probability of 3‐month survival in patients with HRS‐
AKI categorized according to median levels of VCAM‐1
VCAM-1< 2372 ng/ml   








F I G U R E  2   Relationship between systemic inflammatory pattern in patients included in this study and different pathological conditions 
based on a network analysis. Link width and distance to the central point is proportional to the predictive score of the network analysis 
that quantifies the network relationships between the evaluated proteins. Only medically relevant conditions with a predictive score 
corresponding to P ≤ 0.1 are displayed. Conditions as defined in BED (Biological Effectors Database, Anaxomics Biotech)
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this alternative strategy was not possible. Secondly, given the rela‐
tive small sizes of our study populations and the exploratory nature 
of this study, we decided not to implement multiplicity adjustment 
strategies. This study will require future replication and the findings 
in general and the P values in particular should be interpreted with 
caution. Thirdly, although the number of patients studied may ap‐
pear relatively low, it is a quite large sample of patients considering 
the difficulty to perform clinical studies in decompensated cirrhosis 
and the sample size of previous pathogenic and therapeutic stud‐
ies in patients with HRS‐AKI. Finally, levels of cytokines in plasma 
may not reflect the actual concentrations of the same cytokines in 
tissues. However, this is a limitation that can barely be addressed in 
human studies.
In conclusion, patients with HRS‐AKI have marked increase in 
systemic inflammatory profile compared to that of patients without 
AKI and hypovolaemia‐induced AKI, which appears to be indepen‐
dent of associated ACLF, and similar to inflammation observed in key 
systemic inflammatory diseases, such as lupus erythematosus or in‐
flammatory bowel disease. Interestingly, in patients with HRS‐AKI, 
lack of AKI resolution and survival is linked to some specific cyto‐
kines, particularly, VCAM‐1.
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